阻塞性睡眠呼吸暂停加速中期年龄相关性黄斑变性进展:三年前瞻性队列研究
该前瞻性队列研究纳入470例≥50岁中期AMD患者及年龄匹配健康对照,经基线多导睡眠监测和视网膜影像分层,391例完成36个月随访。结果显示AMD合并OSA组复合进展终点发生率为31.4%,显著高于无OSA组的15.2%(P=0.002),且OSA严重程度与AMD进展呈剂量依赖性关联。
要点
- 中期AMD合并OSA患者36个月复合进展风险显著高于无OSA者(31.4% vs 15.2%,P=0.002)。
- OSA严重程度与AMD进展呈剂量依赖关系,重度OSA风险比达2.80(95%CI 1.75-4.47,P<0.001)。
- 中期AMD患者筛查并治疗OSA可能成为保护视力的新策略。
核心结论
- OSA是中期AMD加速进展的独立、剂量依赖性危险因素。
研究设计与样本
- 前瞻性队列研究纳入470例≥50岁中期AMD患者及年龄匹配健康对照,基线行多导睡眠监测和多模态视网膜影像后分层为AMD+OSA组(n=185)、AMD无OSA组(n=185)和健康对照组(n=100),391例完成36个月随访。
主要发现
- 完成随访的391例中(保留率83.2%),AMD+OSA组主要终点发生率为31.4%(48/153),AMD无OSA组为15.2%(24/158),差异有统计学意义(P=0.002)。
- AMD+OSA组与AMD无OSA组相比,视力恶化分别为0.15和0.06 logMAR(P<0.001),玻璃膜疣体积增加分别为0.05和0.02 mm3(P<0.001)。
- Cox回归显示OSA严重程度与AMD进展呈剂量依赖关系:轻度OSA的HR=1.45(95%CI 0.95-2.20,P=0.08),中度OSA的HR=2.10(95%CI 1.35-3.28,P=0.001),重度OSA的HR=2.80(95%CI 1.75-4.47,P<0.001)。
关键数值与推荐
- 主要终点为36个月内复合AMD进展,包括中心性地图样萎缩、新生血管性AMD或≥15个字母的视力下降。
- 次要终点包括视力、玻璃膜疣体积和地图样萎缩面积的变化。
临床怎么用
- 对中期AMD患者应考虑筛查OSA,并对确诊OSA患者进行治疗,可能有助于延缓AMD进展、保护视力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Obstructive sleep apnea (OSA) and age-related macular degeneration (AMD) share pathophysiological mechanisms involving oxidative stress and inflammation. We investigated whether OSA accelerates AMD progression in patients with intermediate AMD. METHODS: This prospective cohort study enrolled 470 patients aged ≥50 years with intermediate AMD and age-matched healthy controls. After baseline polysomnography and multimodal retinal imaging, 470 participants were enrolled and stratified into AMD+OSA (n = 185), AMD-noOSA (n = 185), and healthy controls (n = 100). Of these, 391 completed the 36-month follow-up (AMD+OSA n = 153; AMD-noOSA n = 158; controls n = 80). The primary endpoint was composite AMD progression (central geographic atrophy, neovascular AMD, or ≥15-letter vision loss) over 36 months. Secondary endpoints included changes in visual acuity, drusen volume, and geographic atrophy area. RESULTS: Of 391 participants completing follow-up (83.2% retention), the AMD+OSA group showed significantly higher progression rates. The primary endpoint occurred in 31.4% (48/153) of AMD+OSA versus 15.2% (24/158) of AMD-noOSA patients (P = 0.002). Visual acuity worsened by 0.15 versus 0.06 logarithm of the minimum angle of resolution (P < 0.001), and drusen volume increased by 0.05 versus 0.02 mm3 (P < 0.001), respectively. Cox regression revealed a dose-dependent relationship: mild OSA (hazard ratio [HR] = 1.45; 95% confidence interval [CI], 0.95-2.20; P = 0.08), moderate OSA (HR = 2.10; 95% CI, 1.35-3.28; P = 0.001), and severe OSA (HR = 2.80; 95% CI, 1.75-4.47; P < 0.001) versus no OSA. CONCLUSIONS: OSA is an independent, dose-dependent risk factor for accelerated AMD progression. Screening and treating OSA in patients with intermediate AMD may represent a novel strategy to preserve vision.
引用
- Li Q, Liu D, Zhang M, et al. Obstructive Sleep Apnea Accelerates Progression of Intermediate Age-Related Macular Degeneration: A Three-Year Prospective Cohort Study. Invest Ophthalmol Vis Sci. 2025. PMID: 41533927. doi:10.1167/iovs.66.15.59
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。